Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 8/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | LSS | P48449 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 2/20 | 0.35 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 2/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15408466 | 1.00 | ROCK2 (0.37) | ROCK2HDAC3HDAC1HDAC2LSS | |
| SCHEMBL15408464 | 1.00 | ROCK2 (0.37) | ROCK2HDAC3HDAC1HDAC2LSS | |
| SCHEMBL4491081 | 0.89 | ROCK2 (0.37) | ROCK2HDAC3HDAC1HDAC2LSS | |
| SCHEMBL12237707 | 0.89 | ROCK2 (0.37) | ROCK2HDAC1LSSBCHEACHE | |
| SCHEMBL4491083 | 0.89 | ROCK2 (0.37) | ROCK2HDAC3HDAC1HDAC2LSS | |
| SCHEMBL4504089 | 0.88 | BACE1 (0.43) | ROCK2LSSNAMPTBACE1MAOA | |
| SCHEMBL3157925 | 0.88 | ROCK2 (0.43) | ROCK2HDAC3HDAC1HDAC2LSS | |
| SCHEMBL4487046 | 0.88 | LSS (0.44) | ROCK2LSSSLC2A1 | |
| SCHEMBL3157931 | 0.88 | ROCK2 (0.43) | ROCK2HDAC3HDAC1HDAC2LSS | |
| SCHEMBL4504092 | 0.88 | BACE1 (0.43) | ROCK2LSSNAMPTBACE1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140018372-A1 | CRYSTALLINE FORM OF A INDOLINONE DERIVATIVE AND ITS USE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-16 | — | — | US | disclosed |
| WO-2014009318-A1 | 3-{3-[1 -(4-DIMETHYLAMINOMETHYL-PHENYLAMINO)-1 -PHENYL-METH-(Z)-YLIDENE]-2-OXO-2,3-DIHYDRO-1 H-INDOL-6-YLL-PROPYNOIC ACID ETHYLAMIDE AND ITS USE IN THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-16 | — | — | WO | disclosed |
| US-20140018372-A1 | CRYSTALLINE FORM OF A INDOLINONE DERIVATIVE AND ITS USE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018372-A1 | CRYSTALLINE FORM OF A INDOLINONE DERIVATIVE AND ITS USE | PIR, IDO1, UACA | ROCK2 2267/4885HDAC3 1532/4885HDAC1 1746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.